SG11201805101RA - Nanoliposomes comprising corticosteroid as medicaments and methods to prepare them - Google Patents
Nanoliposomes comprising corticosteroid as medicaments and methods to prepare themInfo
- Publication number
- SG11201805101RA SG11201805101RA SG11201805101RA SG11201805101RA SG11201805101RA SG 11201805101R A SG11201805101R A SG 11201805101RA SG 11201805101R A SG11201805101R A SG 11201805101RA SG 11201805101R A SG11201805101R A SG 11201805101RA SG 11201805101R A SG11201805101R A SG 11201805101RA
- Authority
- SG
- Singapore
- Prior art keywords
- nanyang
- international
- corticosteroid
- nanoliposome
- singapore
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 2
- 239000000232 Lipid Bilayer Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- CWQXQMHSOZUFJS-UHFFFAOYSA-N molybdenum disulfide Chemical compound S=[Mo]=S CWQXQMHSOZUFJS-UHFFFAOYSA-N 0.000 abstract 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 abstract 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 abstract 1
- 229960003099 amcinonide Drugs 0.000 abstract 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 229960003662 desonide Drugs 0.000 abstract 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 abstract 1
- 229960001347 fluocinolone acetonide Drugs 0.000 abstract 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 abstract 1
- 229960000785 fluocinonide Drugs 0.000 abstract 1
- 229960002383 halcinonide Drugs 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 229960001664 mometasone Drugs 0.000 abstract 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000011148 porous material Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 229960005294 triamcinolone Drugs 0.000 abstract 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 abstract 1
- 229960002117 triamcinolone acetonide Drugs 0.000 abstract 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110101111110111111011111111101111011111 International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... ....!;,„. WO 2017/105344 Al 22 June 2017(22.06.2017) WIPO I PCT (51) International Patent Classification: Nanyang Technological University, 50 Nanyang Avenue, A61K 9/127 (2006.01) A61P 9/10 (2006.01) Singapore 639798 (SG). A61K 31/56 (2006.01) (74) Agent: VIERING, JENTSCHURA & PARTNER LLP; (21) International Application Number: P.O Box 1088, Rochor Post Office, Rochor Road, Singa- PCT/SG2016/050584 pore 911833 (SG). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 28 November 2016 (28.11.2016) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (25) Filing Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (26) Publication Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (30) Priority Data: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 10201510370T 17 December 2015 (17.12.2015) SG MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (71) Applicant: NANYANG TECHNOLOGICAL UNIVER- OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SITY [SG/SG]; 50 Nanyang Avenue, Singapore 639798 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (SG). TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: VENKATRAMAN, Subramanian; c/o Nan- yang Technological University, 50 Nanyang Avenue, (84) Designated States (unless otherwise indicated, for every Singapore 639798 (SG). NATARAJAN, Jayaganesh V.; kind of regional protection available): ARIPO (BW, GH, c/o Nanyang Technological University, 50 Nanyang Aven- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, ue, Singapore 639798 (SG). DARWITAN, Anastasia; c/o TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [Continued on next page] Title: NANOLIPOSOMES COMPRISING CORTICOSTEROID AS MEDICAMENTS AND METHODS TO PREPARE (54) = THEM Figure 2 (57) : This invention relates to a nanoliposome comprising at least one outer lipid bilayer and at least one (a) Release Profiles of FA-Loaded Liposomes corticosteroid encapsulated bythe at leastone lipid bilayer, 120 wherein the ratio of the corticosteroid and lipids forming the 100 lipid bilayer is preferably between 0.01 - 0.5, 0.1 - 0.3 or Z 40 0.12 - 0.18. The corticosteroid may be a group B corticoster - so oid, including triamcinolone acetonide, fluocinolone acet - onide, triamcinolone alcohol, mometasone, amcinonide, e 40 budesonide, desonide, fluocinonide and halcinonide. Prefer- ably, the size of the nanoliposome is between 1 0 - 1 000 nm 0 or 50 - 150 nm. The present invention also relates to the use 0 5 10 15 20 25 ao 35 of the nanoliposome of the invention for use as a medicam Time (day) ent and for use in the treatment of a cardiovascular disease. ---4--- DA = 0.15 molimoi --e-- DA =0.15 motimol (with DSPE-PEG 2K) Further, the invention is directed to a method to prepare the nanoliposome of the invention, which may further include an (b) Comparison of Daily FA Release Between DPPC + FA extruding step. (D/1=0.15 mol/mol) with and without DSPE-PEG 2K _ 300 2 250 i 200 i 150 li ; 100 71' 71' 1 6 11 15 21 26 31 en ir) lima (day) 0 li —4-0/1=0.15 motimol —5-- DA = 0.15 mol/rnol (with OSPE-PEG 2K) ,-.... IN li © N O WO 2017/105344 Al MIDEDIMOMOIDIONOIDEMOMMIMBOORIMMEHOIMI TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Published: DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, LT, SE, GA, — with — with international search report (Art. 21(3)) sequence listing part of description (Rule 5.2(a)) GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201510370T | 2015-12-17 | ||
| PCT/SG2016/050584 WO2017105344A1 (en) | 2015-12-17 | 2016-11-28 | Nanoliposomes comprising corticosteroid as medicaments and methods to prepare them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805101RA true SG11201805101RA (en) | 2018-07-30 |
Family
ID=59057346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912650QA SG10201912650QA (en) | 2015-12-17 | 2016-11-28 | Nanoliposomes comprising corticosteroid as medicaments and methods to prepare them |
| SG11201805101RA SG11201805101RA (en) | 2015-12-17 | 2016-11-28 | Nanoliposomes comprising corticosteroid as medicaments and methods to prepare them |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912650QA SG10201912650QA (en) | 2015-12-17 | 2016-11-28 | Nanoliposomes comprising corticosteroid as medicaments and methods to prepare them |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20180360758A1 (en) |
| CN (1) | CN108430457A (en) |
| SG (2) | SG10201912650QA (en) |
| WO (1) | WO2017105344A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201900008745A1 (en) * | 2019-06-12 | 2020-12-12 | Univ Degli Studi Genova | ENGINEERED NANO-LIPOSOMES FOR A TARGETED THERAPY OF ATHEROSCLEROSIS AND THEIR PREPARATION PROCEDURE |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060115523A1 (en) * | 2004-12-01 | 2006-06-01 | Konduri Kameswari S | Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal |
| WO2006027787A1 (en) * | 2004-09-09 | 2006-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal compositions of glucocorticoid and glucocorticoid derivatives |
| EP1919450B1 (en) * | 2005-09-01 | 2014-06-11 | Meda AB | Antihistamine- and corticosteroid-containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders |
| EP2127639A1 (en) * | 2008-05-26 | 2009-12-02 | Universiteit Utrecht Holding B.V. | Corticosteroid containing liposomes for treatment of cardiovascular diseases |
| WO2011150392A1 (en) * | 2010-05-28 | 2011-12-01 | Purdue Research Foundation | Delivery of therapeutic agents to inflamed tissues using folate-targeted agents |
| JP2014532697A (en) * | 2011-11-04 | 2014-12-08 | エンセラドゥス ファーマセウティカルス べー．フェー． | Liposomal corticosteroids for the treatment of inflammatory disorders in humans |
| EP2789348B1 (en) * | 2011-12-07 | 2021-08-04 | Universidade do Minho | Liposomes and corresponding production method |
| CN104173285A (en) * | 2013-05-23 | 2014-12-03 | 上海市第七人民医院 | Preparation method for triamcinolone acetonide acetate ultradeformable nanometer lipid vesicle spraying agent and application to target hypertrophic scars |
-
2016
- 2016-11-28 WO PCT/SG2016/050584 patent/WO2017105344A1/en not_active Ceased
- 2016-11-28 US US16/063,062 patent/US20180360758A1/en not_active Abandoned
- 2016-11-28 SG SG10201912650QA patent/SG10201912650QA/en unknown
- 2016-11-28 SG SG11201805101RA patent/SG11201805101RA/en unknown
- 2016-11-28 CN CN201680074636.8A patent/CN108430457A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108430457A (en) | 2018-08-21 |
| US20180360758A1 (en) | 2018-12-20 |
| SG10201912650QA (en) | 2020-02-27 |
| WO2017105344A1 (en) | 2017-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201901210UA (en) | Ferroelectric memory cells | |
| SG11201807785VA (en) | Neuroactive steroids, compositions, and uses thereof | |
| SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| SG11201811035TA (en) | Core-composite shell microcapsules | |
| SG11201910085UA (en) | Atropine pharmaceutical compositions | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201804807VA (en) | Computer architecture and method for modifying data intake parameters based on a predictive model | |
| SG11201907210YA (en) | Policy communication via control plane signaling | |
| SG11201811237WA (en) | Combination therapies | |
| SG11201805950UA (en) | Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201908783QA (en) | Antigen discovery for t cell receptors isolated from patient tumors recognizing wild-type antigens and potent peptide mimotopes | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201909858TA (en) | Communication device, communication method, program, and communication system | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201407229UA (en) | Substituted pyrazole compounds as lpar antagonists | |
| SG11201902738PA (en) | Vehicle collision avoidance | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809527UA (en) | Methods of treating circadian rhythm sleep disorders | |
| SG11201811246RA (en) | Novel silybum marianum achene extract and uses thereof in dermatology and dermo-cosmetics | |
| SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
| SG11201408759XA (en) | Oil/water-emulsion-type topical compositions containing a retinoid | |
| SG11201804435SA (en) | Network security agent |